ACNS0821 Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
This randomized phase II trial is studying how well giving temozolomide and irinotecan
hydrochloride together with or without bevacizumab works in treating young patients with
recurrent or refractory medulloblastoma or central nervous system (CNS) primitive
neuroectodermal tumors. Drugs used in chemotherapy, such as temozolomide and irinotecan
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can
block tumor growth in different ways. Some block the ability of tumor cells to grow and
spread. Others find tumor cells and help kill them or carry tumor-killing substances to
them. It is not yet known whether temozolomide and irinotecan hydrochloride are more
effective with or without bevacizumab in treating medulloblastoma or CNS primitive
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.